Los Angeles, CANCT06563895Now EnrollingIRB Ready

Transthyretin Amyloidosis Clinical Trial in Los Angeles, CA

Access cutting-edge transthyretin amyloidosis treatment through this clinical trial at a research site in Los Angeles. Study-provided care at no cost to qualified participants.

Sponsored by Eidos Therapeutics, a BridgeBio company

Quick Self-Assessment

See if you qualify for this Los Angeles location

Preparing your pre-screening questions...

Expert Care in Los Angeles

Access transthyretin amyloidosis specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related transthyretin amyloidosis treatment provided free

Apply for This Los Angeles Location

Check if you qualify for this transthyretin amyloidosis clinical trial in Los Angeles, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Los Angeles

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Los Angeles site if eligible
  4. 4Begin participation

About This Transthyretin Amyloidosis Study in Los Angeles

Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque- like substance that accumulates in different organs in the body and can cause damage to the organ. There are two ways that the TTR protein can fall apart. One way occurs as a person ages, where the normal TTR protein can fall apart and form amyloid that may no longer be sufficiently cleared by the body. This type of ATTR is known as wild-type ATTR

Sponsor: Eidos Therapeutics, a BridgeBio company

Who Can Participate

Inclusion Criteria

Male or female ≥ 18 to ≤ 75 years of age inclusive.
Participants must have an established genotype (hetero- or homozygosity) of a TTR gene variant that is known to be pathogenic (eg, V30M/p.V50M, V122I/p.V142I, T60A/p.T80A, or any other pathogenic TTR variant(s)) confirmed by central laboratory prior to randomization.
Participant's age is no more than 10 years (≤ 10) younger than the PADO. Key

Exclusion Criteria

Evidence of ATTR-CM or ATTR-PN.
Presence of a TTR variant known to be phenotypically protective (eg, T119M, R104H).
Current or past treatment with other TTR modifying therapies.
Contraindication to or inability to undergo Cardiac magnetic resonance testing.
Major organ dysfunction, including: kidney disease, liver disease, heart disease (including cardiomyopathy), neuropathy
Other diseases or conditions such has cancer within 3 years, untreated hyperthyroidism or hypothyroidism, type 1 diabetes, active hepatitis B or C, HIV.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Los Angeles?

Yes, this clinical trial (NCT06563895) has an active research site in Los Angeles, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Transthyretin Amyloidosis Treatment Options in Los Angeles, CA

If you're searching for transthyretin amyloidosis treatment options in Los Angeles, CA, this clinical trial (NCT06563895) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Los Angeles research site is actively enrolling participants for this clinical trial. You'll receive care from experienced transthyretin amyloidosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all transthyretin amyloidosis clinical trials near you to find additional studies recruiting in your area.

More Essential Tremor Trials in Los Angeles, CA

See all essential tremor clinical trials recruiting in Los Angeles — not just this study.

Browse Essential Tremor Trials in Los Angeles

Ready to Join in Los Angeles?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Los Angeles, CA